Sarepta Therapeutics reported third quarter 2026 results that exceeded top-line expectations, driven by a resilient legacy PMO franchise that mitigated headwinds from narrowed Elevidys label restrictions. While the company missed on non-GAAP EPS, management demonstrated improved operating discipline by raising the lower end of full-year revenue guidance and narrowing expense outlooks.

Key Highlights

  • Net product revenues reached $323.8 million, supported by $240.3 million from the PMO franchise and $83.5 million from ELEVIDYS.
  • Raised the floor for 2026 total net product revenue guidance by $50 million to a new range of $1.25 billion to $1.3 billion.
  • Non-GAAP operating income turned positive at $22.9 million, a significant improvement from the prior year's $35.7 million operating loss.
  • Ended the quarter with a strong liquidity position of approximately $998.7 million in cash and investments.